Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWN0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $35,258
Award facts
- Contract value 100% obligated
- $35,257.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $35,257.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 30 tablets of Cabometyx 40 mg, an oncology medication. The award, issued on January 29, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group's parent IDC under PPV-G GEN V, designated SPE2DR and awarded November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, positioning the company as one of multiple regional prime vendor contractors. The vendor's established performance across numerous delivery orders for diverse pharmaceutical products—including branded and generic medications, biologics, vaccines, and specialty pharmaceuticals—demonstrates its capability to fulfill the specialized medical supply requirements of military healthcare facilities worldwide. As a small business with consistent federal contracting activity through the Defense Logistics Agency's Medical Supply Chain division, DMS Pharmaceutical Group leverages its operational infrastructure and product portfolio to serve as a critical supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQWN0?
SPE2DR26FQWN0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FQWN0 worth?
The government has obligated $35,258 on SPE2DR26FQWN0.
Is contract SPE2DR26FQWN0 an order under another contract?
Yes. SPE2DR26FQWN0 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWN0 competed?
The extent of competition for SPE2DR26FQWN0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award